Summary
IJF Chart
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICON Public Limited Company (ICLR) Q3 2025 Earnings Call Transcript
ICON Public Limited Company (NASDAQ:ICLR ) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT Company Participants Kate Haven - Vice President of Investor Relations Steven Cutler Barry Balfe - CEO & Director Nigel Clerkin - Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Michael Cherny - Leerink Partners LLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Jailendra Singh - Truist Securities, Inc., Research Division Patrick Donnelly - Citigroup Inc., Research Division Jack Meehan - Nephron Research LLC Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Charles Rhyee - TD Cowen, Research Division Michael Ryskin - BofA Securities, Research Division David Windley - Jefferies LLC, Research Division Kyle Crews - UBS Investment Bank, Research Division Luke Sergott - Barclays Bank PLC, Research Division Christine Rains - William Blair & Company L.L.C.
Icon PLC (ICLR) Surpasses Q3 Earnings and Revenue Estimates
Icon PLC (ICLR) came out with quarterly earnings of $3.31 per share, beating the Zacks Consensus Estimate of $3.28 per share. This compares to earnings of $3.35 per share a year ago.
ICON plc (IJF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has ICON plc ever had a stock split?
ICON plc Profile
| Professional Services Industry | Industrials Sector | Barry Balfe CEO | XHAN Exchange | IE0005711209 ISIN |
| IE Country | 41,250 Employees | - Last Dividend | 13 Aug 2008 Last Split | 15 May 1998 IPO Date |
Overview
ICON Public Limited Company stands as a prominent clinical research organization (CRO) delivering comprehensive outsourced development and commercialization services across Ireland, rest of Europe, the United States, and globally. With its incorporation in 1990 and headquartering in Dublin, Ireland, ICON specializes in facilitating the strategic development, management, and analysis of programs spanning the entire clinical development spectrum from compound selection through to Phase I-IV clinical studies. Catering to the pharmaceutical, biotechnology, medical device industries, and government and public health organizations, ICON is dedicated to advancing medical research and bringing innovations to market more efficiently.
Products and Services
The array of services offered by ICON is versatile, covering every facet of clinical development and commercialization:
- Clinical Development Services: These encompass all stages of drug development, from early phase to peri and post-approval studies, offering comprehensive data solutions alongside site and patient access services. ICON's approach is designed to streamline the clinical trial process, ensuring efficiency and efficacy.
- Clinical Trial Management: ICON provides meticulous management of clinical trials, including consulting, contract staffing, and full study execution, tailored to meet the unique needs of each project and ensure its successful completion.
- Commercial Services: From clinical development strategy and trial design to full study execution and post-market commercialization, ICON offers a range of services aimed at maximizing the market potential of new medical products.
- Laboratory Services: The company’s laboratory services are broad-ranging, encompassing bionanalytical, biomarker, vaccine, good manufacturing practice (GMP), and central laboratory services. ICON delivers reliable and accurate test results, crucial for the success of clinical trials.
- Partnership Models: ICON offers both full-service and functional service partnerships, catering to the varied needs of its customers by providing tailored solutions that align with their strategic objectives.
- Specialized Solutions: This includes a plethora of services such as adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory services, commercial positioning, decentralized and hybrid clinical trials, early clinical development, laboratories, language services, medical imaging, real-world intelligence, and strategic solutions designed to address specific challenges within the clinical trial and pharmaceutical development processes.
